Oxidative Stress in Alzheimer's Disease and Mild Cognitive Impairment with High Sensitivity and Specificity
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Some studies have determined that oxidative stress is a decisive factor in Alzheimer's disease (AD) and even suggested that it is present in the initial phase of mild cognitive impairment (MCI). The aim of our study was to investigate the process of oxidative stress by measuring the level of malondialdehyde (MDA), the specific activity of two peripheral antioxidant defenses (superoxide dismutase (SOD) and ceruloplasmin), and the level of copper in AD and MCI patients and compare those results with healthy subjects. The sample group consisted of 36 patients with AD, 18 patients with MCI, and 33 healthy aged subjects. Blood samples were obtained from each subject. A significantly higher copper level was found in patients with AD and MCI compared to the control group. The levels of MDA showed a similar trend and were higher in patients from the AD and MCI groups than in the control group. It was found that both studied parameters had positive correlation in the whole studied population (r = 0.340; p = 0.001). A stepwise logistic regression analysis was used to identify an optimal combination of these biomarkers. The optimal biomarker combinations were MDA and SOD with area under the curve of 0.803 (0.691-0.915, CI 95%, p < 0.001) for the diagnosis of AD. The optimal cutpoint yielded 88.0% Sensitivity and 70.0% Specificity. The biomarker combinations predicted AD and were markedly superior to individual biomarkers. Our findings support the hypothesis that oxidative stress might represent a sign of AD pathology and could be an early event in the progression of MCI to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metals, Toxicity and Oxidative Stress
Valko, M., Morris, H., & Cronin, M. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053764635 · Cited by 5,018 · cited 2×
“Metals such as copper (Cu) are oxidant agents involved in the formation of free radicals and ROS [10, 16, 17] due to its high redox potential [17, 18].”
BackgroundMild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972 · cited 1×
“It is generally estimated that the rate of progression is almost 50% within 3 years, approximately 15–20% per year, supporting the concept that MCI represents an early stage of AD [28–31].”
BackgroundOxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Evidence of increased oxidative damage in subjects with mild cognitive impairment
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., & Markesbery, W. R. (2005) · Neurology · doi:10.1212/01.wnl.0000156156.13641.ba · Cited by 539
Oxidative stress in Alzheimer disease
Gella, A., & Durany, N. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.1.7402 · Cited by 459
Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology
HUANG, X., MOIR, R. D., TANZI, R. E., BUSH, A. I., & ROGERS, J. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.012 · Cited by 425 · cited 3×
“Metals such as copper (Cu) are oxidant agents involved in the formation of free radicals and ROS [10, 16, 17] due to its high redox potential [17, 18].”
BackgroundPadurariu, M., Ciobica, A., Hritcu, L., Stoica, B., Bild, W., & Stefanescu, C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.033 · Cited by 378 · cited 3×
“The discrepancies observed in the different studies on AD may be due to several factors [34, 35, 38, 45, 48, 49].”
BackgroundResultCauses of oxidative stress in Alzheimer disease
Zhu, X., Su, B., Wang, X., Smith, M. A., & Perry, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7218-4 · Cited by 336
Cited by
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
Ferroptosis: Mechanisms and links with diseases
Yan, H.-F., Zou, T., Tuo, Q.-Z., Xu, S., Li, H., Belaidi, A. A., & Lei, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00428-9 · Cited by 1,471
GPX4, ferroptosis, and diseases
Zhang, W., Liu, Y., Liao, Y., Zhu, C., & Zou, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116512 · Cited by 426
Melatonin and its metabolites vs oxidative stress: From individual actions to collective protection
Galano, A., & Reiter, R. J. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12514 · Cited by 353
Copper and Zinc Dysregulation in Alzheimer’s Disease
Sensi, S. L., Granzotto, A., Siotto, M., & Squitti, R. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.10.001 · Cited by 285
Glutathione peroxidase 4: a new player in neurodegeneration?
Cardoso, B. R., Hare, D. J., Bush, A. I., & Roberts, B. R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.196 · Cited by 281
Galano, A., & Raúl Alvarez‐Idaboy, J. (2019) · International Journal of Quantum Chemistry · doi:10.1002/qua.25665 · Cited by 281
Metals and neurodegenerative diseases. A systematic review
Cicero, C. E., Mostile, G., Vasta, R., Rapisarda, V., Signorelli, S. S., Ferrante, M., Zappia, M., & Nicoletti, A. (2017) · Environmental Research · doi:10.1016/j.envres.2017.07.048 · Cited by 269
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
Seo, E.-J., Fischer, N., & Efferth, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.030 · Cited by 265
Vanillic acid attenuates Aβ1-42-induced oxidative stress and cognitive impairment in mice
Amin, F. U., Shah, S. A., & Kim, M. O. (2017) · Scientific Reports · doi:10.1038/srep40753 · Cited by 204
Zheng, Y., Zhang, X., Zhang, R., Wang, Z., Gan, J., Gao, Q., Yang, L., Xu, P., & Jiang, X. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5314 · Cited by 52
“In addi‑ tion, downstream pro‑inflammatory mediators are activated, thereby affecting neuronal function (44,45).”
BackgroundSTING Deletion Protects Against Amyloid β‐induced Alzheimer's Disease Pathogenesis
Thanos, J. M., Campbell, O. C., Cowan, M. N., Bruch, K. R., Moore, K. A., Ennerfelt, H. E., Natale, N. R., Mangalmurti, A., Kerur, N., & Lukens, J. R. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70305 · Cited by 26
“46 In these studies, we detected lower levels of MDA in whole-brain lysates from 5-month-old STING-deficient 5xFAD mice in comparison to 5xFAD littermate controls (Figure 4F), suggesting that reduced levels of lipid peroxidation are also a hallmark of the improvements in neuronal health seen in…”
Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer’s disease
McIntyre, J. A., Ramsey, C. J., Gitter, B. D., Saykin, A. J., Wagenknecht, D. R., Hyslop, P. A., & Initiative, F. T. A. D. N. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1008464 · Cited by 22
Metadata
- Authors
- López, N., Tormo, C., De Blas, I., Llinares, I., & Alom, J.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-01-10
- Volume
- 33
- Issue
- 3
- Pages
- 823-829
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1733078847
- Cited by
- 134
- References
- 13
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.